High-level expression of podoplanin in benign and malignant soft tissue tumors: Immunohistochemical and quantitative real-time RT-PCR analysis

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 599-607

  Xu, Yongjun ^a   Ogose, Akira ^a   Kawashima, Hiroyuki ^a   Hotta, Tetsuo ^a   Ariizumi, Takashi ^a   Li, Guidong ^a   Umezu, Hajime ^b   Endo, Naoto ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

Immunohistochemistry; Podoplanin; Quantitative real time RT PCR; Soft tissue tumors

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PODOPLANIN;

ALVEOLAR SOFT PART SARCOMA; ARTICLE; BENIGN TUMOR; CELL LINE; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOMA; MALIGNANT NEOPLASTIC DISEASE; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SOFT TISSUE TUMOR; SPINDLE CELL SARCOMA; TUMOR CELL;

ADULT; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MEMBRANE GLYCOPROTEINS; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA; SARCOMA, EWING'S; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551597199     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1141     Document Type: Article

References (44)

1. Wetterwald A, Hofstetter W, Cecchini MG, et al: Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18: 125-132, 1996.
2. Breiteneder-Geleff S, Matsui K, Soleiman A, et al: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151: 1141-1152. 1997.
3. Hong YK, Harvey N, Noh YH, Schacht V, Hirakawa S and Detmar M: Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 225: 351-357, 2002.
4. Marks A, Sutherland DR, Bailey D, et al: Characterization and distribution of an oncofetal antigen (M2A antigen) Expressed on testicular germ cell tumours. Br J Cancer 80: 569-578, 1999.
5. Schacht V, Ramirez MI, Hong YK, et al: T1a/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556, 2003. (Pubitemid 36898332)
6. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166: 913-921, 2005. (Pubitemid 40315647)
7. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 26: 195-200, 2005. (Pubitemid 41379745)
8. Suzuki-Inoue K, Kato Y, Inoue O, et al: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 282: 25993-26001, 2007.
9. Kato Y, Kaneko MK, Kunita A, et al: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 99: 54-61, 2008.
10. Kaneko MK, Kato Y, Kameyama A, et al: Functional glycosylation of human podoplanin: Glycan structure of platelet aggregation-inducing factor. FEBS Lett 581: 331-336, 2007.
11. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M and Osawa M: Molecular identification of Aggrus/T1a as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278: 51599-51605, 2003.
12. Kato Y, Kaneko MK, Kuno A, et al: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 349: 1301-1307, 2006.
13. Ordóñez NG: Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 3: 83-88, 2006.
14. Ordóñez NG: D2-40 and podoplanin are highly specific and sensitive immuno-histochemical markers of epithelioid malignant mesothelioma. Hum Pathol 36: 372-380, 2005.
15. Hantusch B, Kalt R, Krieger S, Puri C and Kerjaschki D: Sp1/Sp3 and DNAmethylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol 8: 20, 2007.
16. Zhang K, Barragan-Adjemian C, Ye L, et al: E11/gp38 selective expression in osteocytes: Regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol 26: 4539-4552, 2006. (Pubitemid 43877574)
17. Williams MC, Cao Y, Hinds A, Rishi AK and Wetterwald A: T1alpha protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus and ciliary epithelia of adult rats. Am J Respir Cell Mol Biol 14: 577-585, 1996. (Pubitemid 126442949)
18. Ramirez MI, Millien G, Hinds A, Cao YX, Seldin DC and Williams MC: T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolous formation at birth. Dev Biol 256: 61-72, 2003.
19. Yu H, Gibson JA, Pinkus GS and Hornick JL: Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol 128: 776-782, 2007.
20. Raica M, Cimpean AM and Ribatti D: The role of podoplanin in tumor progression and metastasis. Anticancer Res 28: 2997-3006, 2008.
21. Marsee DK, Pinkus GS, Hornick JL: Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. Appl Immunohistochem Mol Morphol 17: 102-107, 2009.
22. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Am J Pathol 154: 385-394, 1999.
23. Fukunaga M: Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 46: 396-402, 2005.
24. Kahn HJ, Bailey D and Marks A: Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 15: 434-440, 2002.
25. Naqvi J, Ordonez NG, Luna MA, Williams MD, Weber RS and El-Naggar AK: Epitheloid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol 2: 25-30, 2007.
26. Fujii T, Zen Y, Sato Y, et al: Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. Mod Pathol 21: 125-130, 2008.
27. Roy S, Chu A, Trojanowski JQ and Zhang PJ: D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastoma from renal cell caricinomas. Acta Neuropathol 109: 497-502, 2005. (Pubitemid 40909194)
28. Sonne SB, Herlihy AS, Hoei-Hansen CE, et al: Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch 449: 200-206, 2006.
29. Zayed AE, Abd-Elnaeim MM, Abd-Elghaffar SKh, Hild A, Brehm R and Steger K: Prenatal development of murine gonads with special reference to germ cell differentiation: a morphological and immunohistochemical study. Andrologia 39: 93-100, 2007.
30. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T and Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 111: 483-488, 2006.
31. Mishima K, Kato Y, Kaneko MK, et al: Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol 111: 563-568, 2006.
32. Shibahara J, Kashima T, Kikuchi Y, Kunita A and Fukayama M: Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448: 493-499, 2006.
33. Durchdewald M, Guinea-Viniegra J, Haag D, et al: Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res 68: 6877-6883, 2008.
34. Martín-Villar E, Scholl FG, Gamallo C, Yurrita MM, Muñoz-Guerra M, Cruces J and Quintanilla M: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113: 899-910, 2005.
35. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ and Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107: 563-569, 2006. (Pubitemid 44107217)
36. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al: Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26: 354-360, 2008. (Pubitemid 351171684)
37. Liang H, Wu H, Giorgadze TA, et al: Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol 31: 304-310, 2007.
38. Yu H, Pinkus GS and Hornick JL: Diffuse membranous immunoreactivity for podoplanin ( D2-40 ) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Am J Clin Pathol 128: 767-775, 2007.
39. Jokinen CH, Dadras SS, Goldblum JR, van de Rijn M, West RB and Rubin BP: Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. Am J Clin Pathol 129: 886-893, 2008.
40. Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S and Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119: 4541-4553, 2006.
41. Scholl FG, Gamallo C, Vilar S and Quintanilla M: Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 112: 4601-4613, 1999.
42. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS and Merlino G: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10: 175-181, 2004.
43. Ariizumi T, Ogose A, Kawashima H, et al: Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Pathol Int 60: 193-202, 2010.
44. Suzuki H, Kato Y, Kaneko MK, Okita Y, Narimatsu H and Kato M: Induction of podoplanin by transforming growth factor-ß in human fibrosarcoma. FEBS Lett 582: 341-345, 2008.